Beam Tx (BEAM) - Enterprise Value to EBITDA Ratio
Beam Therapeutics Inc. (BEAM) is developing advanced precision genome editing, leveraging partnerships with industry behemoths and success in anemia therapy. The business valuation based on EV/EBITDA illustrates market expectations, where the parameter reaches 0.00. The absence of commercial products renders cash flows unstable, while long-term patent protection will be tested during rigorous FDA trials.
Comprehensive metric breakdowns and analytics for beamtx.com (BEAM)
- stock price and consensus target price:
- market capitalization indicators:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Beam Therapeutics Inc.|BEAM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Beam Therapeutics|BEAM - Company Aggregate Debts|Debt to Book Capitalization Ratio Beam Tx|BEAM - Long-Term Liabilities|Company Short-Term Debts Beam Therapeutics|Quick Liquidity Indicator beamtx.com
- financial results and valuation multiples details:
BEAM - Net Profit|Future Profit Beam Therapeutics Inc.|BEAM - Market Price to Net Income Ratio|Forward P/E Multiple Beam Therapeutics Inc.|BEAM - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Beam Tx|BEAM - Operating profit before deduction of amortization|Earnings per share for the last twelve months Beam Therapeutics|BEAM - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months beamtx.com|BEAM - Earnings per share increase in current year|Earnings growth forecast for next year Beam Therapeutics Inc.
- company sales and revenue statistics:
Fundamental company analysis:BEAM (Beam Therapeutics Corp)
John Evans' developments in gene editing require colossal capital expenditures, making the analysis of business value relative to operating profit critically important for Beam Therapeutics Inc. (BEAM). This metric sums market capitalization and net debt, dividing them by EBITDA to determine the asset payback period and avoid overpaying for an asset at the peak of overheating, which clearly reflects the current EV/EBITDA level of the company.
Direct competitors
tempus.com - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation QGEN|IONS: Enterprise Value to EBITDA Ratio|repligen.com - Enterprise Value to Operating Income Before Depreciation Ratio|RNA: EV/EBITDA Multiple|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|WGS (Sema4) - EV/EBITDA Multiple|Company Value to EBITDA Ultragenyx Corp RARE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sarepta Therapeutics, Inc. (SRPT)|TWST (twistbioscience.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TXG (10x Genomics)|EV/EBITDA Multiple Intellia Therapeutics Inc NTLA|STOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio BLFS|WVE: EV/EBITDA Multiple|Company Value to EBITDA mazetx.com (MAZE)|Enterprise Value to EBITDA Ratio SION|EV/EBITDA Multiple Prime Medicine Inc|Enterprise Value to EBITDA Ratio TSHA (Taysha)|Enterprise Value to Operating Income Before Depreciation Ratio QURE|EV/EBITDA Multiple MGTX (MeiraGTx Holdings plc)|Total Company Value to Operating Income Before Depreciation Ratio regenxbio.com (RGNX)|Solid Biosciences - EV/EBITDA Multiple|Ocugen Inc (OCGN) - Enterprise Value to EBITDA Ratio|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BNTC - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio DSGN|RCKT: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FDMT|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|ProQR Therapeutics N.V. (PRQR) - Enterprise Value to EBITDA Ratio|CDXS (codexis.com) - Enterprise Value to EBITDA Ratio|SGMO - Total Company Value to Operating Income Before Depreciation Ratio|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MGX|EV/EBITDA Multiple DTIL|GBIO - Company Value to EBITDA|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Phio Pharmaceuticals (PHIO) - Enterprise Value to EBITDA Ratio|MBIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation RNAZ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple immunoprecise.com (IPA)|EV/EBITDA Multiple OMGA (Omega Therapeutics)|singulargenomics.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Company Value to EBITDA Syros Pharmaceuticals Inc.|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals, Inc (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
